Cell and Gene Therapy Market Projected to Reach $105 Billion by 2033 as Clinical Pipeline Expands
Key Insights
The global cell and gene therapy market is expected to exceed $105 billion by 2033, driven by significant expansion in clinical pipelines with Phase I trials experiencing approximately 11% growth.
Cell therapy dominates the market with 61.2% share, reaching $14.66 billion in 2023, while manufacturing costs remain a challenge with CAR-T (search) therapies exceeding $100,000 per patient.
North America leads the market with 43.7% share at $11.97 billion in 2023, supported by advanced regulatory frameworks including the FDA's RMAT designation for accelerated therapy review.
The global cell and gene therapy market is poised for unprecedented growth, with projections indicating the market will exceed $105 billion by 2033, according to new market intelligence data. This expansion is being fueled by a robust clinical pipeline that has experienced significant growth across all development phases, with Phase I trials leading the surge at approximately 11% growth.
Market Dynamics Drive Therapeutic Innovation
The cell therapy segment currently dominates the market landscape, accounting for 61.2% of global market share and reaching $14.66 billion in 2023, up from $13.39 billion in 2022. This growth reflects the strong clinical success of cell therapies, particularly in oncology and regenerative medicine, where CAR-T (search) therapies and stem cell-based treatments have demonstrated high efficacy rates.
A significant milestone occurred in April 2024 when India launched its first indigenously developed CAR-T (search) cell therapy, developed by the Indian Institute of Technology (IIT) Bombay and Tata Memorial Centre. The therapy is being offered at nearly one-tenth of the global cost, highlighting the potential for innovation to address accessibility challenges.
Advanced Delivery Systems Accelerate Development
One of the most significant growth drivers in the market is the increasing utilization of advanced delivery vectors, which are essential for transporting genetic material safely and efficiently into target cells. Traditional delivery systems have faced limitations related to targeting accuracy, immune response, and dosage efficiency, prompting the development of next-generation viral and non-viral vectors.
In May 2023, AGC Biologics introduced its BravoAAV and ProntoLVV viral vector platforms, offering faster, scalable, and reproducible production under Good Manufacturing Practice (GMP) conditions. These platforms are designed to support both clinical and commercial-scale manufacturing. Similarly, Charles River Laboratories International launched reference materials for adeno-associated virus (AAV (search)) and lentiviral vector (search) (LVV) portfolios in May 2024 to streamline research and enable smoother transitions to GMP-quality production.
Manufacturing Costs Present Ongoing Challenges
Despite strong growth prospects, high development costs and complex manufacturing processes remain significant market restraints. Manufacturing costs for CAR-T (search) therapies can exceed $100,000 per patient, while certain gene therapies for rare genetic diseases can cost over $2 million per patient. These high costs create challenges related to reimbursement, scalability, and patient access.
According to simulations by the National Institutes of Health (NIH), annual spending on gene therapies could reach approximately $20.4 billion, even under conservative assumptions. The production of viral vectors and specialized raw materials is both capital- and time-intensive, with limited suppliers further increasing expenses.
Regional Leadership and Regulatory Support
North America dominates the global market, accounting for approximately 43.7% of total market share and reaching $11.97 billion in 2023, up from $10.94 billion in 2022. The region's leadership is supported by a strong biotechnology ecosystem, advanced healthcare infrastructure, and proactive regulatory frameworks.
The U.S. Food and Drug Administration (FDA) has introduced specialized pathways such as the Regenerative Medicine Advanced Therapy (RMAT) designation, which expedites the review of promising therapies. In August 2024, Ocugen received FDA clearance to initiate an expanded access program for OCU400, a modifier gene therapy for retinitis pigmentosa (search), demonstrating continued regulatory support for innovative treatments.
Industry Consolidation and Strategic Partnerships
The competitive landscape features a combination of established pharmaceutical companies and innovative biotechnology firms focusing on expanding clinical pipelines and improving manufacturing capabilities. Key players include Novartis AG with its Kymriah and Zolgensma products, Gilead Sciences through its Kite Pharma division offering Yescarta and Tecartus, and Bristol Myers Squibb (search) with its Breyanzi and Abecma CAR-T (search) therapies.
Strategic acquisitions continue to shape the market, with Merck (search) announcing in August 2024 the completion of its approximately $600 million acquisition of Mirus Bio, reinforcing the company's commitment to supporting viral vector manufacturing from preclinical through commercial production.
Manufacturing Innovation and Decentralization
Recent industry developments highlight the focus on manufacturing innovation and accessibility. In September 2024, CPC launched a new aseptic micro-connector designed specifically for freeze cassettes used in cell and gene therapy processing. Walgreens announced plans in April 2024 to work directly with drug manufacturers to expand patient access through its specialty pharmacy division.
ProPharma (search), in partnership with Italy-based PBL, launched the Cell Factory Box (CF Box) in May 2024—a fully automated system enabling decentralized CGT manufacturing in controlled environments, addressing scalability and accessibility challenges.
Future Outlook and Market Potential
The lentivirus manufacturing segment for advanced therapies is experiencing particular growth, with the gene therapy segment holding 45.6% market share in 2025. Clinical and pilot-scale production currently contributes the highest revenue share, while commercial and large-scale production is expected to grow at 11.6% CAGR between 2026 and 2035.
Pharmaceutical and biotechnology companies represent 62.4% of the end-user market, with research institutes and academic institutions emerging as the fastest-growing segment. The Asia Pacific region is positioned as the fastest-growing market, supported by increasing investment in cell and gene therapy pipelines and government funding for national initiatives.
With strong momentum across research, development, and commercialization, cell and gene therapies are positioned to redefine treatment paradigms and deliver long-term value to healthcare systems worldwide through 2033 and beyond.